As I said in my opening comments, Madam Chair, it could involve more questions in the area of looking into the impact or potential impact on the health system, critical infrastructure or the supply chains that are so important to Canadians right now. It could lengthen the time of the review process, and obviously, we want to signal to investors that if they're contemplating a sale, they should take that into account.
On June 18th, 2020. See this statement in context.